Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Multiple Myeloma
Multiple Myeloma
Janssen reports Phase II data for Darzalex-RVd to treat multiple myeloma
Clinical Trials Arena
Mon, 08/29/22 - 10:32 am
JNJ
Janssen
clinical trials
Darzalex
Revlimid
Velcade
Multiple Myeloma
J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering
Fierce Pharma
Thu, 08/25/22 - 07:43 pm
JNJ
Europe
bispecific antibodies
Multiple Myeloma
Tecvayli
teclistamab
Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma
BioPharma Dive
Wed, 08/10/22 - 11:34 pm
Bristol Myers Squibb
2seventy bio
Abecma
CAR-T
Multiple Myeloma
Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition
Fierce Biotech
Fri, 08/5/22 - 10:42 am
Amgen
BCMA
PSMA
Multiple Myeloma
bispecific antibodies
Janssen secures FDA breakthrough designation for myeloma therapy
Pharmaceutical Business Review
Thu, 06/30/22 - 10:54 am
JNJ
Janssen
breakthrough therapy
FDA
talquetamab
Multiple Myeloma
relapsed or refractory multiple myeloma
ASCO 2022 – Carvykti casts a long shadow
EP Vantage
Mon, 06/6/22 - 10:01 am
ASCO 2022
Carvykti
CAR-T
Arcellx
Gracell
Oricell
Multiple Myeloma
ASCO: J&J, Legend reveal more CAR-T data and a look at Carvykti for earlier myeloma in a difficult population
Fierce Pharma
Fri, 05/27/22 - 10:33 am
ASCO 2022
JNBJ
Legend Biotech
Carvykti
CAR-T
Multiple Myeloma
J&J scores one-two royalty punch against Genmab in blockbuster Darzalex fight
Fierce Pharma
Fri, 04/8/22 - 10:22 am
JNJ
Genmab
Darzalex
Multiple Myeloma
drug royalties
Playing catch-up with J&J, Sanofi taps Blackstone for $300M to fund pivotal trial of subcutaneous Sarclisa
Fierce Pharma
Tue, 03/15/22 - 10:47 am
Sanofi
Blackstone Life Sciences
Sarclisa
Multiple Myeloma
Bristol Myers Squibb's Revlimid finally faces competition in the U.S. with Teva's generic launch
Fierce Pharma
Mon, 03/7/22 - 10:51 pm
Bristol Myers Squibb
Revlimid
Multiple Myeloma
generics
Teva Pharmaceutical
J&J, Legend cell therapy approved by FDA for multiple myeloma
BioPharma Dive
Mon, 02/28/22 - 11:44 pm
JNJ
Legend Biotech
FDA
Multiple Myeloma
Carvykti
CAR-T
Arcellx’s IPO raises $124M to fuel chase of better CAR T-cell therapy for cancer
MedCity News
Tue, 02/8/22 - 09:53 am
Arcellx
IPOs
CAR-T
funding
cell therapy
Multiple Myeloma
Arcellx raises $124M in Wall Street debut to bankroll study of multiple myeloma CAR-T
Fierce Biotech
Fri, 02/4/22 - 11:01 am
Arcellx
IPOs
Multiple Myeloma
Months after pulling only drug from US, Oncopeptides takes back withdrawal request — but stays mum on why
Endpoints
Mon, 01/24/22 - 10:16 am
Oncopeptides
FDA
Pepaxto
Multiple Myeloma
4 Biotechs That Were Winners at ASH
Motley Fool
Mon, 01/3/22 - 10:38 am
ASH2021
Bristol Myers Squibb
Agios Pharmaceuticals
Forma Therapeutics
Bluebird Bio
sickle cell disease
Multiple Myeloma
J&J goes after another FDA approval for a cancer bispecific
Pharmaforum
Thu, 12/30/21 - 10:53 am
JNJ
bispecific antibodies
cancer
FDA
Janssen
teclistamab
Multiple Myeloma
ASH: Sanofi, Johnson & Johnson on collision course with Sarclisa, Darzalex 4-drug regimens in myeloma
Fierce Pharma
Sun, 12/12/21 - 11:33 pm
ASH2021
Sanofi
JNJ
Sarclisa
Darzalex
Multiple Myeloma
J&J and Sanofi's multiple myeloma tit-for-tat continues, as subcutaneous Darzalex wins combo approval
Endpoints
Thu, 12/2/21 - 10:57 am
JNJ
Sanofi
Multiple Myeloma
Sarclisa
Kyprolis
Darzalex
GSK unveils Target the Future, a global, multi-year program to help address key challenges affecting the multiple myeloma community
Indiana Gazette
Wed, 12/1/21 - 11:44 pm
GSK
Target the Future
Multiple Myeloma
Go or go go? J&J’s cell therapy heads to the FDA
EP Vantage
Fri, 10/29/21 - 10:33 am
JNJ
cilta-cel
Multiple Myeloma
FDA
Biomarin
Merck
molnupiravir
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »